Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental pill takes on advanced cancers alongside immunotherapy

NCT ID NCT05594043

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This early-phase trial tests an experimental oral drug, MK-6598, both by itself and in combination with the immunotherapy pembrolizumab (Keytruda) in adults with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. Participants must have tumors that can be biopsied and have already tried or cannot tolerate other standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called MK-6598, given as a tablet, tested alone and with the immunotherapy pembrolizumab (Keytruda)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is an early Phase 1 trial with only 39 participants, focused on safety and dosing. The drug may not prove effective or may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC SOLID TUMORS

Contacts and locations

Locations

  • Cantonal Hospital St.Gallen ( Site 0203)

    Sankt Gallen, 9007, Switzerland

  • Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0100)

    Montreal, Quebec, H2X 0A9, Canada

  • Hôpitaux Universitaires de Genève (HUG) ( Site 0202)

    Geneva, Canton of Geneva, 1211, Switzerland

  • Ospedale Regionale Bellinzona e Valli ( Site 0200)

    Bellinzona, Canton Ticino, 6500, Switzerland

  • Princess Margaret Cancer Centre ( Site 0101)

    Toronto, Ontario, M5G 2M9, Canada

  • Sanford Cancer Center ( Site 0300)

    Sioux Falls, South Dakota, 57104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.